Reactive Stroma and Tumor Associated Macrophages in Prostate Cancer Progression

前列腺癌进展中的反应性基质和肿瘤相关巨噬细胞

基本信息

  • 批准号:
    7978318
  • 负责人:
  • 金额:
    $ 57.39万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2010
  • 资助国家:
    美国
  • 起止时间:
    2010-09-07 至 2015-08-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): The specific mechanisms of how the microenvironment regulates prostate cancer progression remain poorly understood. The combined previous studies of Drs. Pienta and Rowley have revealed that tumor associated macrophages (TAMs) and reactive stroma both promote prostate cancer progression. Dr. Pienta has demonstrated a major role for CCL2 in prostate tumor growth and metastasis through its regulatory role in mediating monocyte / macrophage infiltration into the tumor microenvironment and stimulating a phenotypic change to TAMs within these immune cells to promote tumor growth. Dr. Rowley has demonstrated that human prostate cancer reactive stroma is composed of myofibroblasts that initiate during PIN and continually co-evolve with adjacent carcinoma during organ-confined progression. The overall hypothesis of this application is that TAMs and reactive stroma serve as complementary coregulators of each other and together promote prostate cancer growth in primary and metastatic sites. Specific Aim 1 (Pienta): Define the mechanisms by v/hich TAMs promote myofibroblast differentiation and function. This Aim will: 1). Define the temporal relationship between the presence of TAMs, the development of reactive stroma, and the development of primary and metastatic prostate cancers using novel transgenic mouse models. 2). Determine the role of reactive stroma / myofibroblasts in the recruitment of macrophages using a human cancer / stromal recombination xenograft model. 3). Compare and contrast the factors that are secreted by TAMs that affect the differentiation of myofibroblasts in primary and metastatic prostate cancer sites using a novel vossicle implant model. 4). Assess the effects of disruption of the CCL2 /TAM axis in the bone microenvironment on PCa cell homing, growth in bone and bone destruction using a novel intra-marrow transplant approach. Specific Aim 2 (Rowley): Determine the composition of reactive stroma in prostate cancer bone metastases. This Aim will: 1). Determine for the first time the relationship between the induction of reactive stroma and the induction of TAMs in both primary and metastatic prostate cancers. 2). Compare results obtained in animal models with human disease. Our goal is to define new biomarkers and therapeutic targets for prostate cancer. All of these Aims will use the prostate cancer samples in the Baylor University and U of M SPORE Tissue Banks, including samples obtained through the rapid autopsy program and samples from the mouse models of prostate cancer growth in primary prostate and bone.
描述(由申请人提供):微环境如何调节前列腺癌进展的具体机制仍然知之甚少。Pienta博士和罗利博士先前的研究表明,肿瘤相关巨噬细胞(TAM)和反应性基质都促进前列腺癌的进展。Pienta博士已经证明了CCL 2在前列腺肿瘤生长和转移中的重要作用,通过其调节作用介导单核细胞/巨噬细胞浸润到肿瘤微环境中,并刺激这些免疫细胞内TAM的表型变化以促进肿瘤生长。罗利博士已经证明,人前列腺癌反应性基质由肌成纤维细胞组成,肌成纤维细胞在PIN期间启动,并在器官局限性进展期间与相邻癌持续共同进化。本申请的总体假设是TAM和反应性基质充当彼此的互补共调节剂,并且一起促进前列腺癌在原发部位和转移部位的生长。具体目标1(Pienta):通过TAM促进肌成纤维细胞分化和功能来定义机制。这一目标将:1)。使用新型转基因小鼠模型,确定TAM的存在、反应性间质的发展以及原发性和转移性前列腺癌的发展之间的时间关系。2)。使用人类癌症/间质重组异种移植模型确定反应性间质/肌成纤维细胞在巨噬细胞募集中的作用。(3)第三章。比较和对比TAM分泌的影响原发性和转移性前列腺癌部位肌成纤维细胞分化的因子,使用新的vossicle植入模型。4)。使用新型骨髓内移植方法评估骨微环境中CCL 2/TAM轴的破坏对PCa细胞归巢、骨生长和骨破坏的影响。具体目标2(罗利):确定前列腺癌骨转移中反应性基质的组成。这一目标将:1)。首次确定原发性和转移性前列腺癌中反应性基质的诱导与TAM的诱导之间的关系。2)。将动物模型中获得的结果与人类疾病进行比较。我们的目标是为前列腺癌定义新的生物标志物和治疗靶点。所有这些目标都将使用贝勒大学和U of M SPORE组织库中的前列腺癌样本,包括通过快速尸检程序获得的样本和来自原发性前列腺和骨骼中前列腺癌生长的小鼠模型的样本。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

KENNETH J. PIENTA其他文献

KENNETH J. PIENTA的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('KENNETH J. PIENTA', 18)}}的其他基金

The Johns Hopkins Physical Sciences Oncology Center
约翰·霍普金斯大学物理科学肿瘤学中心
  • 批准号:
    9753736
  • 财政年份:
    2016
  • 资助金额:
    $ 57.39万
  • 项目类别:
The Johns Hopkins Physical Sciences Oncology Center
约翰·霍普金斯大学物理科学肿瘤学中心
  • 批准号:
    9339630
  • 财政年份:
    2016
  • 资助金额:
    $ 57.39万
  • 项目类别:
The JAK2 V617F mutation within B cells and T cells leads to a pro-tumor microenvironment
B 细胞和 T 细胞内的 JAK2 V617F 突变导致促肿瘤微环境
  • 批准号:
    9903606
  • 财政年份:
    2016
  • 资助金额:
    $ 57.39万
  • 项目类别:
The Johns Hopkins Physical Sciences Oncology Center
约翰霍普金斯大学物理科学肿瘤中心
  • 批准号:
    10016193
  • 财政年份:
    2016
  • 资助金额:
    $ 57.39万
  • 项目类别:
Human Sample Acquisition Core (HSAC)
人体样本采集核心 (HSAC)
  • 批准号:
    8555284
  • 财政年份:
    2011
  • 资助金额:
    $ 57.39万
  • 项目类别:
Reactive Stroma and Tumor Associated Macrophages in Prostate Cancer Progression
前列腺癌进展中的反应性基质和肿瘤相关巨噬细胞
  • 批准号:
    8139125
  • 财政年份:
    2010
  • 资助金额:
    $ 57.39万
  • 项目类别:
CTSA INFRASTRUCTURE FOR CLINICAL TRIALS
CTSA 临床试验基础设施
  • 批准号:
    8173854
  • 财政年份:
    2010
  • 资助金额:
    $ 57.39万
  • 项目类别:
CTSA INFRASTRUCTURE FOR PEDIATRIC RESEARCH
CTSA 儿科研究基础设施
  • 批准号:
    8173853
  • 财政年份:
    2010
  • 资助金额:
    $ 57.39万
  • 项目类别:
Reactive Stroma and Tumor Associated Macrophages in Prostate Cancer Progression
前列腺癌进展中的反应性基质和肿瘤相关巨噬细胞
  • 批准号:
    8537843
  • 财政年份:
    2010
  • 资助金额:
    $ 57.39万
  • 项目类别:
Annual Meeting for the Clinical Research Ethics Key Function Committee
临床研究伦理关键职能委员会年会
  • 批准号:
    7916113
  • 财政年份:
    2010
  • 资助金额:
    $ 57.39万
  • 项目类别:

相似海外基金

Quantification of Neurovasculature Changes in a Post-Hemorrhagic Stroke Animal-Model
出血性中风后动物模型中神经血管变化的量化
  • 批准号:
    495434
  • 财政年份:
    2023
  • 资助金额:
    $ 57.39万
  • 项目类别:
Small animal model for evaluating the impacts of cleft lip repairing scar on craniofacial growth and development
评价唇裂修复疤痕对颅面生长发育影响的小动物模型
  • 批准号:
    10642519
  • 财政年份:
    2023
  • 资助金额:
    $ 57.39万
  • 项目类别:
Bioactive Injectable Cell Scaffold for Meniscus Injury Repair in a Large Animal Model
用于大型动物模型半月板损伤修复的生物活性可注射细胞支架
  • 批准号:
    10586596
  • 财政年份:
    2023
  • 资助金额:
    $ 57.39万
  • 项目类别:
A Comparison of Treatment Strategies for Recovery of Swallow and Swallow-Respiratory Coupling Following a Prolonged Liquid Diet in a Young Animal Model
幼年动物模型中长期流质饮食后吞咽恢复和吞咽呼吸耦合治疗策略的比较
  • 批准号:
    10590479
  • 财政年份:
    2023
  • 资助金额:
    $ 57.39万
  • 项目类别:
Diurnal grass rats as a novel animal model of seasonal affective disorder
昼夜草鼠作为季节性情感障碍的新型动物模型
  • 批准号:
    23K06011
  • 财政年份:
    2023
  • 资助金额:
    $ 57.39万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Longitudinal Ocular Changes in Naturally Occurring Glaucoma Animal Model
自然发生的青光眼动物模型的纵向眼部变化
  • 批准号:
    10682117
  • 财政年份:
    2023
  • 资助金额:
    $ 57.39万
  • 项目类别:
A whole animal model for investigation of ingested nanoplastic mixtures and effects on genomic integrity and health
用于研究摄入的纳米塑料混合物及其对基因组完整性和健康影响的整体动物模型
  • 批准号:
    10708517
  • 财政年份:
    2023
  • 资助金额:
    $ 57.39万
  • 项目类别:
A Novel Large Animal Model for Studying the Developmental Potential and Function of LGR5 Stem Cells in Vivo and in Vitro
用于研究 LGR5 干细胞体内外发育潜力和功能的新型大型动物模型
  • 批准号:
    10575566
  • 财政年份:
    2023
  • 资助金额:
    $ 57.39万
  • 项目类别:
Elucidating the pathogenesis of a novel animal model mimicking chronic entrapment neuropathy
阐明模拟慢性卡压性神经病的新型动物模型的发病机制
  • 批准号:
    23K15696
  • 财政年份:
    2023
  • 资助金额:
    $ 57.39万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
The effect of anti-oxidant on swallowing function in an animal model of dysphagia
抗氧化剂对吞咽困难动物模型吞咽功能的影响
  • 批准号:
    23K15867
  • 财政年份:
    2023
  • 资助金额:
    $ 57.39万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了